|
[1]AHMED M.Non-alcoholic fatty liver disease in 2015[J].World J Hepatol,2015,7(11):1450-1459.
|
|
[2]FARRELL GC,WONG VW,CHITTURI S.NAFLD in Asia-as common and important as in the West[J].Nat Rev Gastroenterol Hepatol,2013,10(5):307-318.
|
|
[3]ABD EL-KADER SM,EL-DEN ASHMAWY EM.Non-alcoholic fatty liver disease:the diagnosis and management[J].World J Hepatol,2015,7(6):846-858.
|
|
[4]PAPPACHAN JM,ANTONIO FA,EDAVALATH M,et al.Non-alcoholic fatty liver disease:a diabetologist's perspective[J].Endocrine,2014,45(3):344-353.
|
|
[5]COHEN JC,HORTON JD,HOBBS HH.Human fatty liver disease:old questions and new insights[J].Science,2011,332(6037):1519-1523.
|
|
[6]DAY CP,JAMES OF.Steatohepatitis:a tale of two“hits”?[J].Gastroenterology,1998,114(4):842-845.
|
|
[7]DONGIOVANNI P,ROMEO S,VALENTI L.Hepatocellular carcinoma in nonalcoholic fatty liver:role of environmental and genetic factors[J].World J Gastroenterol,2014,20(36):12945-12955.
|
|
[8]GIBY VG,AJITH TA.Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease[J].World J Hepatol,2014,6(8):570-579.
|
|
[9]FIRENZUOLI F,GORI L.Herbal medicine today:clinical and research issues[J].Evid Based Complement Alternat Med,2007,4(Suppl 1):37-40.
|
|
[10]HEEBLL S,THOMSEN KL,PEDERSEN SB,et al.Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease[J].World J Hepatol,2014,6(4):188-198.
|
|
[11]HEEBLL S,THOMSEN KL,CLOUSTON A,et al.Effect of resveratrol on experimental non-alcoholic steatohepatitis[J].Pharmacol Res,2015,95-96:34-41.
|
|
[12]CHACHAY VS,MACDONALD GA,MARTIN JH,et al.Resveratrol does not benefit patients with nonalcoholic fatty liver disease[J].Clin Gastroenterol Hepatol,2014,12(12):2092-2103.
|
|
[13]FAGHIHZADEH F,ADIBI P,RAFIEI R,et al.Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease[J].Nutr Res,2014,34(10):837-843.
|
|
[14]CHANG JJ,HSU MJ,HUANG HP,et al.Mulberry anthocyanins inhibit oleic acid induced lipid accumulation by reduction of lipogenesis and promotion of hepatic lipid clearance[J].J Agric Food Chem,2013,61(25):6069-6076.
|
|
[15]VALENTI L,RISO P,MAZZOCCHI A,et al.Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease[J].Oxid Med Cell Longev,2013,2013:145421.
|
|
[16]TANG X,SHEN T,JIANG X,et al.Purified anthocyanins from bilberry and black currant attenuate hepatic mitochondrial dysfunction and steatohepatitis in mice with methionine and choline deficiency[J].J Agric Food Chem,2015,63(2):552-561.
|
|
[17]ZHANG PW,CHEN FX,LI D,et al.A CONSORT-compliant,randomized,double-blind,placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease[J].Medicine(Baltimore),2015,94(20):e758.
|
|
[18]XIAO J,HO CT,LIONG EC,et al.Epigallocatechin gallate attenuates fibrosis,oxidative stress,and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD,PI3 K/Akt/Fox O1,and NFkappa B pathways[J].Eur J Nutr,2014,53(1):187-199.
|
|
[19]GAN L,MENG ZJ,XIONG RB,et al.Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice[J].Acta Pharmacol Sin,2015,36(5):597-605.
|
|
[20]SAKATA R,NAKAMURA T,TORIMURA T,et al.Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease(NAFLD)patients:a doubleblind placebo-controlled study[J].Int J Mol Med,2013,32(5):989-994.
|
|
[21]YESIL A,YILMAZ Y.Review article:coffee consumption,the metabolic syndrome and non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther,2013,38(9):1038-1044.
|
|
[22]CHEN S,TEOH NC,CHITTURI S,et al.Coffee and non-alcoholic fatty liver disease:brewing evidence for hepatoprotection?[J].J Gastroenterol Hepatol,2014,29(3):435-441.
|
|
[23]BAMBHA K,WILSON LA,UNALP A,et al.Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis[J].Liver Int,2014,34(8):1250-1258.
|
|
[24]ZELBER-SAGI S,SALOMONE F,WEBB M,et al.Coffee consumption and nonalcoholic fatty liver onset:a prospective study in the general population[J].Transl Res,2015,165(3):428-436.
|
|
[25]TAKEMURA S,MINAMIYAMA Y,KODAI S,et al.S-Allyl cysteine improves nonalcoholic fatty liver disease in type 2 diabetes Otsuka Long-Evans Tokushima Fatty rats via regulation of hepatic lipogenesis and glucose metabolism[J].J Clin Biochem Nutr,2013,53(2):94-101.
|
|
[26]XIAO J,GUO R,FUNG ML,et al.Garlic-derived S-allylmercaptocysteine ameliorates nonalcoholic fatty liver disease in a rat model through inhibition of apoptosis and enhancing autophagy[J].Evid Based Complement Alternat Med,2013,2013:642920.
|
|
[27]LAI YS,CHEN WC,HO CT,et al.Garlic essential oil protects against obesity-triggered nonalcoholic fatty liver disease through modulation of lipid metabolism and oxidative stress[J].J Agric Food Chem,2014,62(25):5897-5906.
|
|
[28]SAHEBKAR A.Potential efficacy of ginger as a natural supplement for nonalcoholic fatty liver disease[J].World J Gastroenterol,2011,17(2):271-272.
|
|
[29]GAO H,GUAN T,LI C,et al.Treatment with ginger ameliorates fructose-induced fatty liver and hypertriglyceridemia in rats:modulation of the hepatic carbohydrate response element-binding protein-mediated pathway[J].Evid Based Complement Alternat Med,2012,2012:570948.
|
|
[30]MONTEIRO J,LESLIE M,MOGHADASIAN MH,et al.The role of n-6 and n-3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease[J].Food Funct,2014,5(3):426-435.
|
|
[31]KIM JK,LEE KS,LEE DK,et al.Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice[J].Exp Mol Med,2014,46:e127.
|
|
[32]CAPANNI M,CALELLA F,BIAGINI MR,et al.Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease:a pilot study[J].Aliment Pharmacol Ther,2006,23(8):1143-1151.
|
|
[33]PARKER HM,JOHNSON NA,BURDON CA,et al.Omega-3 supplementation and non-alcoholic fatty liver disease:a systematic review and meta-analysis[J].J Hepatol,2012,56(4):944-951.
|
|
[34]DASARATHY S,DASARATHY J,KHIYAMI A,et al.Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis[J].J Clin Gastroenterol,2015,49(2):137-144.
|
|
[35]HNCU N,ROMAN G,NITC,et al.Metabolic syndrome-practical approach[J].Rom J Intern Med,2004,42(2):2372-2345.
|
|
[36]SATO K,ARAI H,MIZUNO A,et al.Dietary palatinose and oleic acid ameliorate disorders of glucose and lipid metabolism in Zucker fatty rats[J].J Nutr,2007,137(8):1908-1915.
|
|
[37]NIGAM P,BHATT S,MISRA A,et al.Effect of a 6-month intervention with cooking oils containing a high concentration of monounsaturated fatty acids(olive and canola oils)compared with control oil in male Asian Indians with nonalcoholic fatty liver disease[J].Diabetes Technol Ther,2014,16(4):255-261.
|
|
[38]RANASINGHE P,JAYAWARDANA R,GALAPPATHTHY P,et al.Efficacy and safety of'true'cinnamon(Cinnamomum zeylanicum)as a pharmaceutical agent in diabetes:a systematic review and meta-analysis[J].Diabet Med,2012,29(12):1480-1492.
|
|
[39]ASKARI F,RASHIDKHANI B,HEKMATDOOST A.Cinnamon may have therapeutic benefits on lipid profile,liver enzymes,insulin resistance,and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients[J].Nutr Res,2014,34(2):143-148.
|
|
[40]SURAPANENI KM,JAINU M.Pioglitazone,quercetin and hydroxy citric acid effect on hepatic biomarkers in Non Alcoholic Steatohepatitis[J].Pharmacognosy Res,2014,6(2):153-162.
|
|
[41]PISONERO-VAQUERO S,MARTNEZ-FERRERAS,GARCAMEDIAVILLA MV,et al.Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/AKT pathway in a diet-induced mouse model of nonalcoholic fatty liver disease[J].Mol Nutr Food Res,2015,59(5):879-893.
|
|
[42]ISHIKAWA H,TAKAKI A,TSUZAKI R,et al.L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway[J].PLo S One,2014,9(7):e100627.
|
|
[43]BAE JC,LEE WY,YOON KH,et al.Improvement of nonalcoholic fatty liver disease with carnitine-orotate complex in type 2 diabetes(CORONA):a randomized controlled trial[J].Diabetes Care,2015,38(7):1245-1252.
|
DownLoad: